EMCURE PHARMACEUTICALS L Latest Share Price (EMCURE)
TODAY IN ONE LINE
EMCURE rose 1.6% on light volume, outperforming Nifty's -0.5% move.
With a market cap of ₹33,768.5 Cr., it trades at a P/E of 33.37. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
EMCURE PHARMACEUTICALS L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 28.8% YoY
- ●High Capital EfficiencyROCE of 16.3% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.8%
- ●Healthy Operating MarginsOPM is structurally strong at 20.3%
- ●High Promoter HoldingPromoters hold 77.6% skin-in-the-game
- ●FII AccumulationFII holding increased by 1.53% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest EMCURE PHARMACEUTICALS L News
What changed recently?
Recent events, corporate actions, and announcements.
EMCURE PHARMACEUTICALS L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for EMCURE PHARMACEUTICALS L, framed against the sector median so the premium or discount is obvious at a glance.
EMCURE PHARMACEUTICALS L trades at a P/E of 33.37× and P/B of 6.82×, against the Healthcare sector median P/E of 43.34×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
EMCURE PHARMACEUTICALS L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for EMCURE PHARMACEUTICALS L — derived from the latest tape, not yesterday's close.
EMCURE PHARMACEUTICALS L last traded at ₹1,782.6 with an intraday range of ₹1,716–₹1,811.1 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1782.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2014.00 | +231.40 | +12.98% |
| R3 | 1918.90 | +136.30 | +7.65% |
| R2 | 1865.00 | +82.40 | +4.62% |
| R1 | 1823.80 | +41.20 | +2.31% |
| PIVOT | 1769.90 | -12.70 | -0.71% |
| CURRENT | 1782.60 | — | — |
| S1 | 1728.70 | -53.90 | -3.02% |
| S2 | 1674.80 | -107.80 | -6.05% |
| S3 | 1633.60 | -149.00 | -8.36% |
| S4 | 1538.50 | -244.10 | -13.69% |
EMCURE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1729.3–₹1746.9
Trading Above opening range, showing Bullishness
EMCURE PHARMACEUTICALS L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for EMCURE PHARMACEUTICALS L — consolidated or standalone — with margins, YoY growth and key ratios inline.
EMCURE PHARMACEUTICALS L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹33,768.5 Cr. and reported EPS of ₹15.50.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 9,204 | 9,204 ▲ 0.0% |
| Sales Growth YoY %Derived | 16.56% | 16.56% |
| Other Income | 13 | 13 ▲ 0.0% |
| Total Income | 9,216 | 9,216 ▲ 0.0% |
| 3,657 | 3,657 ▲ 0.0% | |
| Gross ProfitDerived | 5,546 | 5,546 ▲ 0.0% |
| Gross Margin %Derived | 60.26% | 60.26% |
| 3,682 | 3,682 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 1,865 | 1,865 ▲ 0.0% |
| OPM %Derived | 20.26% | 20.26% |
| 527 | 527 ▲ 0.0% | |
| Profit Before Tax (PBT) | 1,287 | 1,287 ▲ 0.0% |
| 346 | 346 ▲ 0.0% | |
| Effective Tax %Derived | 26.87% | 26.87% |
| Total Profit for Period | 941 | 941 ▲ 0.0% |
| Less: Non-controlling Interests | 17 | 17 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 924 | 924 ▲ 0.0% |
| Net Profit Margin %Derived | 10.04% | 10.04% |
| PAT Growth YoY %Derived | 35.67% | 35.67% |
| Earnings Per Share (EPS ₹) | 48.76 | 48.76 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 19 | 19 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 166 | 166 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 7,929 | 7,929 ▲ 0.0% |
| Material Cost % of RevenueDerived | 18.39% | 18.39% |
| Employee Cost % of RevenueDerived | 16.87% | 16.87% |
| Other Cost % of RevenueDerived | 23.14% | 23.14% |
| Interest Coverage (x)Derived | 10.09x | 10.09x |
| Period | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 7,896 | 7,896 ▲ 0.0% | 9,204 ▲ 16.6% | 9,204 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 16.56% | 16.56% | |
| Other Income | 67 | 67 ▲ 0.0% | 13 ▼ 81.2% | 13 ▲ 0.0% | |
| Total Income | 7,963 | 7,963 ▲ 0.0% | 9,216 ▲ 15.7% | 9,216 ▲ 0.0% | |
3,147 | 3,147 ▲ 0.0% | 3,657 ▲ 16.2% | 3,657 ▲ 0.0% | ||
| Gross ProfitDerived | 4,749 | 4,749 ▲ 0.0% | 5,546 ▲ 16.8% | 5,546 ▲ 0.0% | |
| Gross Margin %Derived | 60.15% | 60.15% | 60.26% | 60.26% | |
3,275 | 3,275 ▲ 0.0% | 3,682 ▲ 12.4% | 3,682 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 1,474 | 1,474 ▲ 0.0% | 1,865 ▲ 26.5% | 1,865 ▲ 0.0% | |
| OPM %Derived | 18.67% | 18.67% | 20.26% | 20.26% | |
550 | 550 ▲ 0.0% | 527 ▼ 4.0% | 527 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 971 | 971 ▲ 0.0% | 1,287 ▲ 32.5% | 1,287 ▲ 0.0% | |
264 | 264 ▲ 0.0% | 346 ▲ 31.1% | 346 ▲ 0.0% | ||
| Effective Tax %Derived | 27.17% | 27.17% | 26.87% | 26.87% | |
| Total Profit for Period | 707 | 707 ▲ 0.0% | 941 ▲ 33.0% | 941 ▲ 0.0% | |
| Less: Non-controlling Interests | 26 | 26 ▲ 0.0% | 17 ▼ 35.3% | 17 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 681 | 681 ▲ 0.0% | 924 ▲ 35.7% | 924 ▲ 0.0% | |
| Net Profit Margin %Derived | 8.63% | 8.63% | 10.04% | 10.04% | |
| PAT Growth YoY %Derived | — | — | 35.67% | 35.67% | |
| Earnings Per Share (EPS ₹) | 35.96 | 35.96 ▲ 0.0% | 48.76 ▲ 35.6% | 48.76 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 19 | 19 ▲ 0.0% | 19 ▲ 0.1% | 19 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 31 | 31 ▲ 0.0% | 166 ▲ 427.5% | 166 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 6,992 | 6,992 ▲ 0.0% | 7,929 ▲ 13.4% | 7,929 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 19.34% | 19.34% | 18.39% | 18.39% | |
| Employee Cost % of RevenueDerived | 18.32% | 18.32% | 16.87% | 16.87% | |
| Other Cost % of RevenueDerived | 23.16% | 23.16% | 23.14% | 23.14% | |
| Interest Coverage (x)Derived | 6.20x | 6.20x | 10.09x | 10.09x |
EMCURE PHARMACEUTICALS L segment analysis : revenue and profit mix.
Disclosed business segments at EMCURE PHARMACEUTICALS L with their share of revenue and profit, switchable between consolidated and standalone reporting.
EMCURE PHARMACEUTICALS L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for EMCURE PHARMACEUTICALS L.
Our AI distills the core fundamental drivers supporting EMCURE PHARMACEUTICALS L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
EMCURE PHARMACEUTICALS L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 28.8% YoY, demonstrating strong earnings momentum and operational efficiency.
ROE 19.75% and ROCE 16.28% exceed peer medians, reflecting superior capital deployment efficiency.
TTM revenue growth 16.70% outpaces industry average, showcasing robust market expansion capability.
Promoter holding 77.6% signals strong long-term commitment and alignment with shareholder interests.
Operating margin 14.92% indicates solid profitability and competitive positioning in pharma sector.
Key Risks.
P/E ratio 37.47x trades at premium valuation, limiting upside and increasing downside risk significantly.
Dividend yield 0.19% extremely low, offering minimal income to shareholders seeking regular returns.
Operating cash flow ₹256 Cr covers only 58% of net profit; earnings quality concern flagged.
Free cash flow negative ₹525 Cr reflects heavy capex burn, constraining liquidity and flexibility.
Payout ratio 6.14% constrains shareholder distributions, limiting appeal to income-focused investors.
Flip Conditions.
Valuation risk. a P/E above 43 (~1.0× the sector multiple of 43.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
EMCURE PHARMACEUTICALS L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — EMCURE PHARMACEUTICALS L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
EMCURE PHARMACEUTICALS L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for EMCURE PHARMACEUTICALS L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
EMCURE PHARMACEUTICALS L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for EMCURE PHARMACEUTICALS L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in EMCURE PHARMACEUTICALS L stood at 53.4% of traded volume, against a 20-day average of 55.2%.
EMCURE PHARMACEUTICALS L announcements: results, concalls, ratings, M&A.
Filings EMCURE PHARMACEUTICALS L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
EMCURE PHARMACEUTICALS L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 181 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Amalgamation/Merger
Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the…
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Emcure Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Trading Window
Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
EMCURE PHARMACEUTICALS L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue EMCURE PHARMACEUTICALS L has declared, sequenced by announce and record date.
EMCURE PHARMACEUTICALS L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About EMCURE PHARMACEUTICALS L: business, sector, key facts.
What EMCURE PHARMACEUTICALS L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
EMCURE PHARMACEUTICALS L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: EMCURE, BSE: 544210.
Emcure Pharmaceuticals Limited is a global pharmaceutical company specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Their diverse portfolio spans numerous therapeutic areas, encompassing treatments for gynecological conditions, cardiovascular diseases, infections, HIV, respiratory illnesses, gastrointestinal disorders, pain, blood-related issues, cancer (oncology/antineoplastics), diabetes, neurological conditions, dermatological problems, and other health concerns. Additionally, they offer vitamins, minerals, and nutritional supplements, showcasing a commitment to comprehensive healthcare solutions.
Emcure's manufacturing capabilities are extensive and sophisticated. They employ diverse drug development platforms, including expertise in chiral molecules, complex active pharmaceutical ingredients (APIs), oral medications, iron-based products, photochemistry-based drugs, liposomal and lyophilized injectables, high-potency drugs, biotherapeutics, and innovative drug delivery systems. This broad technological base allows them to produce a variety of drug formulations to meet diverse market needs and patient requirements.
The company markets its products under several well-established brand names, including Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo. These brands represent the company's commitment to providing quality and effective medications across a spectrum of therapeutic areas. The use of established brand names aids in market recognition and builds consumer trust, a critical aspect of success in the competitive pharmaceutical industry.
Founded in 1981 and headquartered in Pune, India, Emcure Pharmaceuticals has a long history of innovation and growth within the pharmaceutical sector. Their continued investment in research and development across multiple therapeutic platforms, combined with their diverse manufacturing capabilities and established brand presence, positions them for continued success in the global pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about EMCURE PHARMACEUTICALS L (EMCURE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of EMCURE PHARMACEUTICALS L (EMCURE)?
The current share price of EMCURE PHARMACEUTICALS L (EMCURE) is ₹1,782.60. Today, the stock has gained by ₹27.50 (1.57%), trading in a range of ₹1,716.00 to ₹1,811.10. The stock opened at ₹1,746.00 with a trading volume of 1,13,203 shares.
02Is EMCURE PHARMACEUTICALS L stock a good investment for long-term?
EMCURE PHARMACEUTICALS L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹33,768.5 Cr., P/E ratio of 33.37, ROE of 19.75%, and ROCE of 16.28%. The dividend yield stands at 0.2%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of EMCURE PHARMACEUTICALS L stock?
The 52-week high price of EMCURE PHARMACEUTICALS L (EMCURE) is ₹2,100.70, while the 52-week low is ₹1,306.50. Currently trading at ₹1,782.60, the stock is 36.44% above its 52-week low and 15.14% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy EMCURE PHARMACEUTICALS L stock at the current price?
Whether to buy EMCURE PHARMACEUTICALS L stock at ₹1,782.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 33.37 and P/B ratio of 6.82. Today's performance shows a gain of 1.57%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of EMCURE PHARMACEUTICALS L and when is the next dividend?
EMCURE PHARMACEUTICALS L offers a dividend yield of 0.2%, which means for every ₹100 invested at the current price of ₹1,782.60, you can expect to receive approximately ₹0.20 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of EMCURE PHARMACEUTICALS L?
EMCURE PHARMACEUTICALS L's key financial metrics include: P/E Ratio: 33.37, P/B Ratio: 6.82, ROE: 19.75%, ROCE: 16.28%, Dividend Yield: 0.2%, EPS: ₹15.50, Book Value: ₹262.37, and Debt-to-Equity: 0.37. The company's market cap stands at ₹33,768.5 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is EMCURE PHARMACEUTICALS L stock performing today in the market?
EMCURE PHARMACEUTICALS L stock opened at ₹1,746.00 and is currently trading at ₹1,782.60, showing a gain of ₹27.50 (1.57%). The intraday high is ₹1,811.10 and low is ₹1,716.00. The trading volume stands at 1,13,203 shares, indicating moderate market participation today.
08What is the P/E ratio of EMCURE PHARMACEUTICALS L and what does it indicate?
EMCURE PHARMACEUTICALS L has a Price-to-Earnings (P/E) ratio of 33.37, which means investors are willing to pay 33.37 for every ₹1 of earnings. With an EPS of ₹15.50, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about EMCURE PHARMACEUTICALS L (EMCURE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.